Maternal Health Pandemic Response Act
Summary
The Maternal Health Pandemic Response Act (S.4550) is an early-stage authorization bill that would allocate up to $130M for CDC maternal health data collection. It has not been passed or funded. Market impact is minimal and indirect.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Authorization of $130M for CDC maternal health data programs — no actual funding yet.
- 2.Early-stage bill (referred to committee) with no hearings scheduled — low passage probability in 119th Congress.
- 3.No direct revenue impact for healthcare companies — tickers included at confidence floor due to distant inference.
Market Implications
No near-term market implications. The bill does not create procurement, subsidies, or regulatory changes that affect corporate earnings. If appropriated and implemented, improved maternal health data could subtly shift R&D priorities at $LLY (diabetes/pregnancy) and (medical devices), but this is a 3-5 year horizon with very low confidence.
Full Analysis
- On May 18, 2026, Senator Warren introduced S.4550, the Maternal Health Pandemic Response Act. It was read twice and referred to the Senate HELP Committee. The bill is in early legislative stages; no hearings or markups have occurred. 2) The bill authorizes $100M for the CDC's SET-Net program and $30M for ERASE MM program funding. Authorization is a ceiling, not an appropriation. Actual spending requires a separate appropriations bill that has not been introduced. 3) The bill's mechanism is purely data collection and surveillance grants to state/local health departments. It does not mandate drug coverage, device procurement, or clinical protocols. Pharmaceutical and medical device companies face no direct obligations or revenue opportunities. 4) The healthcare sector is broadly affected only in the sense that improved maternal health data may inform future policy, but this is years away and dependent on appropriations. 5) The timeline requires committee passage, full Senate vote, House companion bill, conference, and then appropriations — a multi-year path with low probability in the current session.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Authorizes $130M for CDC data collection, surveillance, and research on maternal health outcomes during public health emergencies. No mandated procurement, no regulatory changes for pharmaceutical companies.
Who must act
Centers for Disease Control and Prevention (CDC)
What happens
CDC receives authorization to spend up to $130M on surveillance infrastructure and capacity building for health departments. No direct financial obligation or opportunity for drug manufacturers.
Stock impact
Lilly's maternal health portfolio (e.g., diabetes/pregnancy) is not directly addressed. The bill funds government data systems, not drug development or purchasing. Indirect benefit if future policy relies on this data, but no near-term revenue change.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HELP Copays Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
INSULIN Act of 2026
To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.
To strengthen the 340B drug discount program.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →